Work

A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.

Year: 2007

Type: article

Study design: Clinical Trial

Source: UCL Discovery (University College London)

Authors: Branimir I. Šikić, Heather A. Wakelee, Margaret von Mehren, Nancy Lewis, E. Ruth Plummer, A H Calvert, Norma Lynn Fox, Elizabeth Kumm, Suzanne F. Jones, Howard A. Burris

Institutions: Human Genome Sciences (United States), Fox Chase Cancer Center, Sarah Cannon Research Institute, Stanford University

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1934014346

FWCI: 2.274

Cites:

Cited by: 36

Related to: 20